LINC02356

Across TCGA pan-cancer cohorts, LINC02356 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated LINC02356 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LINC02356 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC02356 expression acts as an unfavorable survival marker, although some lineages such as CESC and ESCA show a favorable association.

LIHC, CESC, and ESCA are the cancer types where LINC02356 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	II,III,IV	0.159	0.281	.003	45	view →
CESC	OS	Median	All	0.713	0.445	<.001	38	view →
ESCA	OS	Tertile	III,IV	0.667	0.309	.005	34	view →
BLCA	OS	Median	All	0.762	0.592	.009	28	view →
THCA	OS	Median	All	0.956	0.993	.002	27	view →
KICH	DFS	Median	III,IV	0.373	1.000	.008	24	view →
LAML	DFS	Quartile	All	0.206	0.552	<.001	24	view →
SKCM	OS	Median	IV	0.896	0.190	.012	23	view →
OV	OS	Quartile	All	0.278	0.378	.033	14	view →
PRAD	DFS	Median	All	0.722	0.868	.018	14	view →
READ	DFS	Quartile	II,III,IV	0.142	0.765	.003	12	view →
ACC	DFS	Median	II,III,IV	0.405	0.658	.012	11	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

LINC02356–LIHC (DFS)

Open the LIHC breakdown →